STAT+: HHS tries pushing pharma to the negotiating table
And more biotech news stories, brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. Today, we’re hearing more about President Trump’s “most-favored nation” plan for drug pricing, Recursion’s case for why the company laid off 20% of its staff, and more.
HHS tries pushing pharma to the negotiating table
The Trump administration is pressuring pharmaceutical companies to negotiate drug prices down to levels seen in other wealthy nations, invoking a “most-favored nation” clause as leverage. While industry executives await specifics on which drugs and price targets could be in play, the Department of Health and Human Services is insisting companies already have the guidance they need, STAT’s Daniel Payne reports.
